N-[7-(Hydroxyamino)-7-oxoheptyl]-4-(methyl-2-pyrazinylamino)benzamide | 1316214-53-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-[7-(Hydroxyamino)-7-oxoheptyl]-4-(methyl-2-pyrazinylamino)benzamide
• 英文别名: N-[7-(hydroxyamino)-7-oxoheptyl]-4-[methyl(pyrazin-2-yl)amino]benzamide
• CAS: 1316214-53-5
• 化学式: C₁₉H₂₅N₅O₃
• 分子量: 371.4
• InChiKey: MBOGFJVUHQTVMV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  27
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  107
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Biomarkers to identify patients that will respond to treatment and treating such patients
  申请人：Acetylon Pharmaceuticals, Inc.

  公开号：US10648038B2

  公开（公告）日：2020-05-12

  The invention relates to methods for using biomarkers to identify cancer patients that will or are likely to respond to treatment. Specifically, the invention relates to the use of one or more of three association studies of cancer types, gene mutations, or gene expression levels in order to identify cancer patients that will or are likely to respond to treatment with a histone deacetylase (HDAC) inhibitor, alone or in combination with another cancer treatment. The methods may, optionally, further include treating such patient with an HDAC inhibitor, alone or in combination with another cancer treatment.

  本发明涉及使用生物标志物来鉴定将会或可能对治疗产生反应的癌症患者的方法。具体地说，本发明涉及使用癌症类型、基因突变或基因表达水平三者中的一种或多种关联研究，以确定将对或可能对组蛋白去乙酰化酶（HDAC）抑制剂单独或与另一种癌症治疗方法联合治疗产生反应的癌症患者。可选地，这些方法还可进一步包括用 HDAC 抑制剂单独或与另一种癌症治疗方法联合治疗此类患者。
• REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF
  申请人：Acetylon Pharmaceuticals, Inc.

  公开号：EP2526093B1

  公开（公告）日：2016-08-17
• BIOMARKERS TO IDENTIFY PATIENTS THAT WILL RESPOND TO TREATMENT AND TREATING SUCH PATIENTS
  申请人：Acetylon Pharmaceuticals, Inc.

  公开号：EP2839037B1

  公开（公告）日：2018-12-26
• Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof
  申请人：van Duzer John H.

  公开号：US20120190693A1

  公开（公告）日：2012-07-26

  The present invention relates to novel “reverse amide” compounds comprising a zinc chelator group, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6.
• Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease
  申请人：Raje Noopur

  公开号：US20140378385A1

  公开（公告）日：2014-12-25

  This invention relates to methods for treating bone disease associated with osteoclast activation using HDAC6 selective inhibitors, e.g., small molecule inhibitors such as reverse amide compounds.